I n the clinical outcome trial PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive), the antidiabetic thiazolidinedione (TZD) pioglitazone demonstrated beneficial effects with respect to macrovascular events in patients with type 2 diabetes. 1 These vasculo-protective effects have been underscored by smaller clinical trials showing a reduction of inflammatory biomarkers, an inhibition of intima-media thickness (IMT) progression and an improvement in endothelial function. [2] [3] [4] [5] [6] A recently published study (PERISCOPE) examined the effect of pioglitazone vs. glimepiride treatment on the progression of coronary artery disease in patients with type 2 diabetes. 7 A total of 543 patients were enrolled in the study; the progression of coronary artery disease was assessed by intravascular ultrasound in a double-blind randomised multicentre trial. Patients received 1-4 mg glimepiride or 15-45 mg pioglitazone (once daily) for a total of 18 months. Some 360 patients completed the trial. In patients receiving glimepiride, intravascular ultrasound revealed a mean increase in plaque volume of 0.73% whilst in the pioglitazone-treated group plaque volume significantly decreased by 0.16%. At entry, glycosylated haemoglobin (HbA 1C ) levels were 7.4% in both groups; pioglitazone treatment was associated with a significantly greater decrease in HbA 1C (0.5% vs. 0.36% in the glimepiride group). In addition, pioglitazone significantly increased high-density lipoprotein (HDL)-cholesterol levels and lowered triglycerides. With respect to side effects, patients in the glimepiride group experienced significantly more hypoglycaemic episodes whereas pioglitazone treatment was associated with a significant increase in fractures (3% vs. 0%) and peripheral oedema. There was no significant difference in hospitalisation due to cardiac compensation. The authors conclude from their study that, in patients with type 2 diabetes and coronary artery disease, pioglitazone therapy compared to glimepiride leads to a significant reduction in the progression of arteriosclerotic lesions.
This study shows for the first time that pioglitazone treatment significantly reduces the progression of coronary artery disease. Previous studies have demonstrated that both pioglitazone and rosiglitazone lead to a reduction of neointima volume after coronary stent implantation in patients with or without diabetes. Moreover, previous studies with both TZDs revealed that these drugs limit the progression of IMT of the carotid artery. Therefore, the data from PERISCOPE are in accordance with previous results on changes in plaque and vessel wall morphology. Overall, the PERISCOPE data and the IMT results for the carotid artery suggest that pioglitazone may lead to plaque regression and potentially to plaque stabilisation. Such effects are currently considered vasculoprotective but to date it remains unclear whether regression of arteriosclerosis in the coronary artery is indeed associated with a reduction of cardiovascular events. In the light of PROactive, the results of PERISCOPE suggest that some of the beneficial effects observed in PROactive may also be due to a plaque-reducing and plaque-stabilising effect. However, to what extent such mechanisms may contribute to a reduction of incident myocardial infarction and cardiovascular events is unclear. In addition, it remains unclear whether the improvement in glycaemic control and the effects of pioglitazone on the lipid profile play a causal role in the favourable results seen in PERISCOPE.
Overall, the PERISCOPE study adds to the beneficial effects of pioglitazone recorded in patients with diabetes and coronary artery disease but, with respect to the reduction of cardiovascular morbidity and mortality, PERISCOPE does not really elucidate the mechanisms that may contribute to a cardiovascular benefit of pioglitazone treatment.
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